Immunohistochemical evaluation of O6-methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma

Neuropathology

Volumn 34, Issue 3, 2014, Pages 268-276

  Miyazaki, Masaya ^a   Nishihara, Hiroshi ^a,g   Terasaka, Shunsuke ^a   Kobayashi, Hiroyuki ^a   Yamaguchi, Shigeru ^a   Ito, Tamio ^b   Kamoshima, Yuuta ^c   Fujimoto, Shin ^d   Kaneko, Sadao ^d   Katoh, Masahito ^e   Ishii, Nobuaki ^f   Mohri, Hiromi ^g   Tanino, Mishie ^a   Kimura, Taichi ^a   Tanaka, Shinya ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Nakamura Memorial Hospital   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d Kashiwaba Neurosurgical Hospital   (Japan)

^e Hokkaido Neurosurgical Mem Hospital   (Japan)

^f Keiwakai Ebetsu Hospital   (Japan)

^g Hokuto Hospital   (Japan)

Author keywords

Glioblastoma; Immunohistochemistry; MGMT; Survival analysis; Temozolomide

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; CANCER PROGNOSIS; FEMALE; GENDER; GLIOBLASTOMA; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SCORING SYSTEM; BIOSYNTHESIS; BRAIN TUMOR; ENZYMOLOGY; EVALUATION STUDY; GENE EXPRESSION REGULATION; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE; TRENDS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84901693194     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/neup.12091     Document Type: Article

References (43)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System, 4th edn. Lyons: IARC Press, 2007.
2. Stupp R, Mason WP, van den Bent MJ etal. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
3. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60: 166-193.
4. Pinto LW, Araujo MB, Vettore AL etal. Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis. Virchows Arch 2008; 452: 481-490.
5. Homma T, Fukushima T, Vaccarella S etal. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 2006; 65: 846-854.
6. Hilton DA, Penney M, Pobereskin L, Sanders H, Love S. Histological indicators of prognosis in glioblastomas: retinoblastoma protein expression and oligodendroglial differentiation indicate improved survival. Histopathology 2004; 44: 555-560.
7. Kraus JA, Lamszus K, Glesmann N etal. Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol (Berl) 2001; 101: 311-320.
8. Salvati M, Formichella AI, D'Elia A etal. Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases. J Neurooncol 2009; 94: 129-134.
9. Miller CR, Dunham CP, Scheithauer BW, Perry A. Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 2006; 24: 5419-5426.
10. Kanno H, Nishihara H, Narita T etal. Prognostic implication of histological oligodendroglial tumor component: clinicopathological analysis of 111 cases of malignant gliomas. PLoS ONE 2012; 7: e41669.
11. Mrugala MM, Chamberlain MC. Mechanisms of disease: temozolomide and glioblastoma - look to the future. Nat Clin Pract Oncol 2008; 5: 476-486.
12. Cheng CL, Johnson SP, Keir ST etal. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 2005; 4: 1364-1368.
13. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 2005; 65: 6394-6400.
14. Kokkinakis DM, Bocangel DB, Schold SC, Moschel RC, Pegg AE. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1, 3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. Clin Cancer Res 2001; 7: 421-428.
15. Hegi ME, Diserens AC, Gorlia T etal. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
16. Everhard S, Tost J, El Abdalaoui H etal. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro-oncol 2009; 11: 348-356.
17. Stupp R, Hegi ME, Mason WP etal. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
18. Esteller M, Garcia-Foncillas J, Andion E etal. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-1354.
19. Felsberg J, Rapp M, Loeser S etal. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 2009; 15: 6683-6693.
20. Stupp R, Hegi ME, Neyns B etal. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28: 2712-2718.
21. Hegi ME, Diserens AC, Godard S etal. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10: 1871-1874.
22. Karayan-Tapon L, Quillien V, Guilhot J etal. Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol 2010; 97: 311-322.
23. Lechapt-Zalcman E, Levallet G, Dugue AE etal. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. Cancer 2012; 118: 4545-4554.
24. Hsu CY, Lin SC, Ho HL etal. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma. Am J Surg Pathol 2013; 37: 264-271.
25. Lalezari S, Chou AP, Tran A etal. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro-oncol 2013; 15: 370-381.
26. Cao VT, Jung TY, Jung S etal. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery 2009; 65: 866-875, discussion 75.
27. Preusser M, Charles Janzer R, Felsberg J etal. Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 2008; 18: 520-532.
28. Rodriguez FJ, Thibodeau SN, Jenkins RB etal. MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol 2008; 16: 59-65.
29. Brell M, Ibanez J, Tortosa A. O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction. BMC Cancer 2011; 11: 35.
30. Anda T, Shabani HK, Tsunoda K etal. Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis. Neurol Res 2003; 25: 241-248.
31. Chinot OL, Barrie M, Fuentes S etal. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 2007; 25: 1470-1475.
32. Yan H, Parsons DW, Jin G etal. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773.
33. Laws ER, Parney IF, Huang W etal. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003; 99: 467-473.
34. Salminen E, Nuutinen JM, Huhtala S. Multivariate analysis of prognostic factors in 106 patients with malignant glioma. Eur J Cancer 1996; 32A: 1918-1923.
35. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999; 17: 1983-1987.
36. Yachi K, Watanabe T, Ohta T etal. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas. Int J Oncol 2008; 33: 469-475.
37. Sonoda Y, Yokosawa M, Saito R etal. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol 2010; 15: 352-358.
38. Friedman HS, McLendon RE, Kerby T etal. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998; 16: 3851-3857.
39. Cao Y, Tsien CI, Shen Z etal. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol 2005; 23: 4127-4136.
40. Chhipa RR, Bhat MK. Bystander killing of breast cancer MCF-7 cells by MDA-MB-231 cells exposed to 5-fluorouracil is mediated via Fas. J Cell Biochem 2007; 101: 68-79.
41. Merle P, Morvan D, Caillaud D, Demidem A. Chemotherapy-induced bystander effect in response to several chloroethylnitrosoureas: an origin independent of DNA damage? Anticancer Res 2008; 28: 21-27.
42. Gorman S, Tosetto M, Lyng F etal. Radiation and chemotherapy bystander effects induce early genomic instability events: telomere shortening and bridge formation coupled with mitochondrial dysfunction. Mutat Res 2009; 669: 131-138.
43. Kohsaka S, Takahashi K, Wang L etal. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Cancer Lett 2013; 331: 68-75.